Alkem Laboratories Declares Interim Dividend of ₹43, Approves Q3 FY26 Results
Alkem Laboratories declared an interim dividend of ₹43 per share, payable March 6, 2026. The company reported Q3 FY26 revenue of ₹37,368 million, up 10.7% YoY. Net profit rose 1.6% to ₹6,360 million. Alkem also signed a term sheet to acquire a majority stake in Occlutech Holding AG.
The declaration of a significant interim dividend and a strategic acquisition in the medical devices sector are material events that are likely to have a high impact on the company's financial performance, market position, and shareholder value.
The positive sentiment is driven by the declaration of an interim dividend, revenue growth, and the strategic acquisition announcement, indicating positive business development and shareholder returns.
Alkem Laboratories Limited announced the outcome of its Board Meeting held on February 13, 2026. The Board approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended December 31, 2025. Additionally, the company declared an interim dividend of ₹43 per equity share for the financial year 2025-2026. The record date for this interim dividend is February 20, 2026, with the payment date set for March 6, 2026.
In its financial results, Alkem reported a total revenue from operations of ₹37,368 million for the third quarter of FY26, marking a 10.7% year-on-year growth. EBITDA stood at ₹8,280 million, a 9.0% YoY increase, with an EBITDA margin of 22.2%. Net Profit after Non-Controlling Interest was ₹6,360 million, a 1.6% YoY growth. The company also reported R&D expenses of ₹1,390 million, representing 3.7% of total revenue from operations. An exceptional item of ₹528 million was noted, primarily related to the impact of newly notified Labour Codes.
Domestically, India sales grew by 5.5% YoY to ₹24,959 million in Q3 FY26. International sales increased by 26.6% YoY to ₹12,157 million, with US sales contributing ₹7,533 million (18.8% YoY growth) and Non-US sales at ₹4,624 million (41.6% YoY growth).
The company also announced the execution of a binding term sheet to acquire a majority stake in Occlutech Holding AG, a global medical devices company specializing in minimally invasive cardiac implants, through its subsidiary Alkem MedTech Pvt Ltd. This strategic acquisition aims to expand Alkem MedTech's presence in cardiovascular and orthopaedics markets.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.